DERIVATIVES OF 2-AMINOPYRIDINE AS ADENOSINE A2B RECEPTOR ANTAGONISTS AND LIGANDS OF THE MELATONIN MT3 RECEPTORS

The present invention relates to pyridine derivatives of formula (I): (see formula I) as A2B adenosine receptor antagonists and ligands of MT3 melatonin receptor, to processes for their preparation, to pharmaceutical compositions comprising said compounds and to the use of said for manufacturing a m...

Full description

Saved in:
Bibliographic Details
Main Authors MENDOZA LIZALDEZ, ADELA, CASTRO- PALOMINO LARIA, JULIO CESAR, CAMACHO GOMEZ, JUAN ALBERTO
Format Patent
LanguageEnglish
French
Published 19.01.2021
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to pyridine derivatives of formula (I): (see formula I) as A2B adenosine receptor antagonists and ligands of MT3 melatonin receptor, to processes for their preparation, to pharmaceutical compositions comprising said compounds and to the use of said for manufacturing a medicament for the treatment of pathological conditions or diseases that can improve by antagonizing the adenosine A2B receptor and by inhibition of MT3 melatonin receptor, such as respiratory disease, metabolic disorders, neurological disorders and cancer. La présente invention concerne de nouveaux dérivés pyridine de formule (I) en tant qu'antagonistes du récepteur A2B de l'adénosine et ligands du récepteur MT3 de la mélatonine, des procédés pour leur préparation, des compositions pharmaceutiques comprenant lesdits composés et l'utilisation de ces derniers pour la fabrication d'un médicament destiné au traitement d'états pathologiques ou de maladies qui peuvent s'améliorer en antagonisant le récepteur A2B de l'adénosine et en inhibant le récepteur MT3 de la mélatonine, tels qu'une maladie respiratoire, des troubles métaboliques, des troubles neurologiques et le cancer.
Bibliography:Application Number: CA20162977905